VCG
CORT icon

Vantage Consulting Group’s Corcept Therapeutics CORT Stock Holding History

Vantage Consulting Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-868
Closed -$23K – 419
2020
Q4 		$23K Buy
+868
New +$18.3K ﹤0.01% 813

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vantage Consulting Group's CORT Position: Q1 2021 in Review

Vantage Consulting Group sold out of Corcept Therapeutics (CORT) in Q1 2021, closing a stake of 868 shares — an estimated $23K sold.

Vantage Consulting Group first reported a position in CORT in Q4 2020 and held it in 1 quarter. The position peaked at $23K in Q4 2020. 209 funds tracked by Wall St. Rank hold CORT as of Q1 2021.

  • Vantage Consulting Group reported no remaining Corcept Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 868 Corcept Therapeutics shares in Q1 2021, an estimated $23K.
  • Vantage Consulting Group first reported a position in Corcept Therapeutics in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Corcept Therapeutics position peaked at $23K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.